Vistin Pharma ASA : Approval of annual accounts
Oslo, Norway, 28 April 2016
The Board of Directors in Vistin Pharma ASA ("Vistin Pharma") has on 27 April 2016 approved the Directors' report and consolidated financial statements for Vistin Pharma for 2015. Compared to the preliminary results for the full-year 2015, published on 23 February, the consolidated net profit has been reduced by NOK 2.3 million. The adjustment is primarily related to a provision for a limited number of batches of metformin sold in 2015, which may be returned to Vistin Pharma in Q2 2016, due to a quality incident. Please refer to the first quarter 2016 financial report for further details.
The annual report for 2015 will be published together with the call for the Annual General Meeting.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Vistin Pharma ASA via GlobeNewswire
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Vistin Pharma ASA via GlobeNewswire
HUG#2007540
